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Abstract
Background—Hepatitis B has been reported to be high in HIV-infected African populations.
However, the impact of this co-infection on the survival of HIV-infected Africans on long-term
highly active antiretroviral therapy (HAART) remains poorly characterised. We investigated the
impact of HBV/HIV co-infection on survival of HIV infected patients undergoing antiretroviral
therapy in a West African population.
Methods—This was a clinic-based cohort study of HIV-infected adults enrolled in Nigeria, West
Africa. Study subjects (9,758) were screened for hepatitis B and hepatitis C at HAART initiation.
Kaplan-Meier survival and Cox proportional hazards models were used to estimate probability of
survival and to identify predictors of mortality respectively, based on hepatitis B surface antigen
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status. All patients had signed an informed written consent before enrolment into the study; and
we additionally obtained permission for secondary use of data from the Harvard institutional
review board.
Results—Patients were followed up for a median of 41 months (interquartile range: 30–62
months) during which, 181 (1.9%) patients died. Most of the deaths; 143 (79.0%) occurred prior to
availability of Tenofovir. Among those that were on antiretroviral therapy, hepatitis B co-infected
patients experienced a significantly lower survival than HIV mono-infected patients at 74 months
of follow up (94% vs. 97%; p=0.0097). Generally, hepatitis B co-infection: HBsAg-positive/HIV-
positive (Hazards Rate [HR]; 1.5: 95% CI 1.09–2.11), co-morbid tuberculosis (HR; 2.2: 95% CI
1.57–2.96) and male gender (HR; 1.5: 95% CI 1.08–2.00) were significantly predictive of
mortality. Categorising the patients based on use of Tenofovir, HBV infection failed to become a
predictor of mortality among those on Tenofovir-containing HAART.
Conclusions—HBsAg-positive status was associated with reduced survival and was an
independent predictor of mortality in this African HIV cohort on HAART. However, Tenofovir
annulled the impact of HBV on mortality of HIV patients in the present study cohort.
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Introduction
Viral hepatitis infection is the leading cause of cirrhosis and primary liver cancer in Africa
[1], where HBsAg prevalence is up to 20% in the general population [2]. Owing to shared
routes of transmission, hepatitis infection rates among HIV-infected patients are
significantly higher than in the general population [3,4].
Since the global scale-up of HAART, numerous studies have shown that the efficacy of
HAART in suppression of HIV in Africa is comparable to that obtained in resource-rich
countries [5–7], though there are conflicting data on whether HBV co-infection affects HIV
suppression [8–10]. In the developed world setting, liver disease has emerged as a leading
cause of death in the era of HAART [11–13] and viral hepatitis co-infection plays an
important role in the progression to cirrhosis in hepatitis B and hepatitis C patients, who are
co-infected with HIV [14]. This pattern has continued despite increasing availability and
administration of HBV-active HAART.
The role of viral hepatitis and consequent chronic liver disease on mortality has not been
widely studied in HIV-infected African populations [15,16], but some studies have noted
high death rates during the initial period of ART [17,18]. However, most of the published
studies have been small [5–7]. We have recently published a high prevalence (18%) of
HBsAg in 19,408 HIV-infected patients from an African population [19]. In the current
report, we present the largest study to date that explores the role of HBV and HIV co-
infection on survival of HIV patients in an African setting. Knowledge of the prognostic
effect of liver-related conditions, such as hepatitis B, which is highly endemic in the West
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African region, would help inform guidelines on screening and treatment with a potential to
reduce excess mortality in HIV-infected patients.
Nigeria is categorised as a low income country, with a population of over 150 million and an
estimated HIV prevalence of 4.4% [20] and HBsAg prevalence rates of up to 20% [21]. The
aims of the present study were to assess the impact of hepatitis B infection, determined by
HBsAg seropositivity, on the survival of HIV-infected individuals and to identify predictors
of mortality during the HAART era in a large cohort of Nigerian patients.
Methods
Study setting and patients
The study was conducted as part of the “AIDS Prevention Initiative in Nigeria” (APIN)
programme, affiliated to the Jos University Teaching Hospital (JUTH), Jos, Plateau State in
the north-central region of Nigeria. Most patients enrolled into the JUTH/APIN programme
were detected through Voluntary Counselling and Testing (VCT) services in adjacent
communities. Hospitalised patients were investigated on clinical suspicion or referred from
nearby health centres. Subjects found to be reactive to HIV by ELISA were confirmed by
Western blot assay prior to enrolment. Liver function tests (LFTs), full blood count, HIV
RNA and CD4 cell counts were measured in all recruited patients at baseline who were also
screened for tuberculosis (TB), prior to commencement of HAART, following the Nigeria
national HIV treatment guidelines (www.naca.gov.ng). From June 2004 to December 2010,
19,408 HIV-infected individuals had been recruited in the JUTH/APIN programme and
were being monitored, on HAART and/or on anti-tuberculosis drugs. This number was
estimated at 13% of all HIV-infected patients within the catchment area [20]. Onsite and
offsite training was provided to personnel working at JUTH/APIN by HIV specialists from
the Harvard School of Public Health (Boston, Massachusetts), Northwestern University
(Chicago, Illinois) and Johns Hopkins University (Baltimore, Maryland), USA.
All patients were subjected to pre-treatment counselling. A patient tracking team,
responsible for providing support to all enrolled patients (in terms of adherence fostering
and to trace missing patients) was put in place in 2006. Treatment support groups (Hope
Support), comprising mostly of HIV-infected patients, were set up within the clinic and
surrounding communities.
PK, the guarantor of the study) obtained ethical approval for the present study from the
Ethics Committee of JUTH and an additional Institutional Review Board (IRB) of Harvard
School of Public Health, USA.
Laboratory testing
Before recruitment into the APIN programme, subjects were screened for HIV using Rapid
HIV test kits and subsequently confirmed by Western Blot assay. HBsAg was determined
using Enzyme immunoassay (EIA) (Monolisa HBsAg Ultra3; BioRad, Hercules, CA, USA).
HCV antibody was tested using third generation enzyme immunoassay (DIA.PRO
Diagnostic, Bioprobessrl, Milan, Italy). HIV RNA levels were measured using Roche
COBAS Amplicor HIV-1 monitor test version 1.5 (Roche Diagnostics, GmbH, Mannheim,
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Germany) with a detection limit of 400 copies/mL (Figure 1). Flow cytometry was used to
determine CD4+ T-cell count (Partec, GmbH, Munster, Germany).
Recruitment, treatment, monitoring and endpoints
Initial first-line antiretroviral (ARV) in 2004 included Stavudine/Zidovudine, Lamivudine
and Efavirenz/Nevirapine. Abacavir and Truvada® (Tenofovir plus Emtricitabine) have been
administered since 2007 at APIN. Additionally, second-line treatment with protease
inhibitors, in cases of treatment failure also became available since early 2007. However,
during 2004 to 2006, Tenofovir and second-line agents were not available and HAART was
not individualised. During 2007–2010, those patients commencing HAART that were co-
infected with HBV, as well as those requiring second line agents, for virological failure were
given ARVs containing Tenofovir.
Patients with CD4 cell counts below 200 cells/mm3were prescribed co-trimoxazole 960mg
once a day, as prophylaxis for P. neumocystisjiroveci pneumonia (PCP). After an initial 4
weeks of fortnightly dispensing, HAART drugs were provided on a monthly basis to those
patients on ART. Paper-based format of data entry was ensured by nurses, physicians and
trained clinical officers and same day computerised data entry was carried out by Data
Officers and supervised by a Data Manager. Personal information, medical history, physical
examination, laboratory investigation and chest X ray reports comprised the initial records.
Follow-up blood tests performed every 3 months, including LFTs, FBC, HIVRNA and CD4
cell count. Drug-related hepatotoxicity was defined as alanine aminotransferase (ALT)
values ≥ 5 fold over the upper limit of the normal range (ULN) (41 iu/ mL for JUTH), or if ≥
3.5 fold over ULN if baseline ALT was above ULN.
As HBV DNA and HCV RNA assays were not available routinely for this cohort, subjects
were defined as having HBV and HCV infection if they tested positive for hepatitis B
surface antigen (HBsAg) and hepatitis C antibody (HCV antibody), respectively on baseline
blood samples.
The main end-point of our study was all-cause mortality. Most deaths were reported through
the activities of the Tracking team and Hope Support groups. Other outcomes that were
censored included those that stopped treatment (detected by pharmacy records), transfer to
another health centre or lost to follow-up.
Statistical analyses
The profile of how the patients were selected for analyses is presented in figure 1. Patients
were included only if they had hepatitis B and hepatitis C screening performed on their sera
at baseline. Apart from over 7000 patients who did not have one or both HBV and HCV
screening, we additionally excluded those that were recruited after December 2010, and
those with incomplete information (gender, age or under 15 yrs).
Kaplan-Meier models were used to estimate survival of the patient groups, while a Cox
proportional hazard modelling was applied to identify independent predictors of mortality.
Univariate analysis was embarked upon initially; and when a statistically significant
association was detected, the variable was fitted into the multivariate model and hazard
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ratios calculated. Subsequently, we analysed the hazards of death for those patients on TDF-
containing HAART, as well as for those not on TDF-containing HAART. Analyses were
accomplished using MedCalc for Windows, version 9.5.0.0 (MedCalc Software,
Mariakerke, Belgium). P values less than 0.05 were considered statistically significant.
Results
Baseline characteristics
Of the 9,748 adults that were commenced on HAART, 6,523 (66.9%) were women. The
median age of the study population was 33 years (range 15–80 yrs.) and 5,915 (60.7%) of
the patients had commenced HAART during the initial period, 2004–2006. The period of the
study was defined based on availability of Tenofovir (HBV potent ARV) in the regimen for
the patients commencing HAART. On this basis, initial period was 2004–2006 and later
period was 2007–2010.
Summary of the baseline characteristics of patients recruited in the study is presented in
Table 1. TB treatment was administered to 1,641 (16.8%) patients. For those that had CD4
results at baseline, there was a significantly higher median CD4 cell count in women than in
men (M: 146 (95% CI=136–156) cells/mm3; F: 188 (95%CI=179–195) cells/mm3;
p<0.0001). The median baseline HIV RNA load was log104.52 (95% CI=4.50–4.55)(M:
4.6(95%CI=4.6–4.7) copies/mL; F:4.5(95%CI=4.4–4.5) copies/mL; p<0.0001). HBsAg-
positive rate was common in this study cohort; 1951 (20.0%). Liver disease was documented
in only 23 (0.2%) of the patients.
Survival analyses
Of those patients that were on HAART, 181 patients (1.9%) died during the follow-up
period. One hundred and forty-three (79.0%) of those that died started ART during the
initial period (2004–2006). Male gender, age ≥40 years at recruitment, co-morbid
tuberculosis, HBsAg positivity, and recruitment during the initial phase of the study were all
significantly associated with death (Table 2). Patients that were co-infected with HBV
suffered a lower survival rate, compared to patient’s negative for HBsAg (Figure 2). The
survival probability of HBsAg-positive versus HBsAg-negative patients at 78 months of
follow-up was 94% and 97%, respectively (p=0.01). This was the case particularly for men;
as HBV co-infection did not result in survival differences in women. HBsAg-positive men
had lower survival, compared to HIV mono-infected men (HIV-positive/HBsAg-positive:
88.5%; HIV-positive/HBsAg-negative: 96.5%; p=0.04).
Fitting the non AIDS-related factors (ie excluding HIV viral load and CD4 cell count) into
the Cox regression multivariate model, independent predictors of death were found to be
male sex, co-morbid tuberculosis and HBV infection. The hazard of mortality was
significantly reduced in patients who started HAART during 2007–2010 (HR: 0.64 [95% CI:
0.42–0.88]), compared to those enrolled during the earlier phase of the programme
(p=0.0081). Intriguingly, HBsAg-positivity, male gender and enrolment that is more recent
ceased to be significant in those that were on TDF-containing HAART.
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As the majority of the deaths occurred during the initial follow-up period, we performed an
additional Cox proportional hazard analysis of death during 12 months from recruitment into
the study. Age ≥ 40 yrs at recruitment, HBV infection (HBsAg-positive) and enrolment
during 2004–2006 were significant predictors of mortality during the early follow-up period.
Discussion
In this African HIV-infected cohort of 9,758 patients on HAART, followed up for a median
period of 41 months, we determined the impact of HBV infection on survival and studied
independent predictors of mortality of HIV-infected patients undergoing antiretroviral
therapy. HIV/HBV co-infection was found to be significantly associated with a lower
probability of survival, compared to HIV mono-infection. On the other hand, recent
recruitment into the APIN programme was significantly associated with reduced rate of
death in both groups. Apart from HBV co-infection, tuberculosis and male sex were also
significantly associated with mortality.
Two studies from South Africa found conflicting outcomes regarding the impact of HBV co-
infection on HIV mortality [8,10]. Hoffman and colleagues in 2008 reported similar
probability of deaths in HBV/HIV and HIV mono-infected patients over a 72-week period
[10]. In contrast, Matthews and colleagues observed a significantly higher mortality in HBV
co-infected patients, compared to HIV mono-infected 1,771 patients in South Africa over 48
weeks follow-up duration [8]. Our findings corroborated those of a large study of HIV-
infected men in the US in which non AIDS-related mortality was highest among HIV/HBV-
infected patients, despite being on HBV-active HAART [9] and in which no association
between HBV infection and higher rates of HIV virologic failure was found. In contrast to
the study in the US however, we found that HBV was not a predictor of mortality when
these African HIV patients were on Tenofovir-containing HAART.
The reasons for the negative impact of HBsAg status on mortality are not fully understood,
but it is unlikely to be related to accentuation of HIV replication, as we found similar levels
of virologic suppression in co-infected versus HIV mono-infected patients in an earlier study
of this cohort [19]. HBV infection in this population frequently occurs early in life and is
postulated to precede HIV infection [22] by which time liver damage may be irreversible,
annulling the anticipated response from HAART. Inflammatory response commonly occurs
during the early phase of HAART [23] and could have contributed to the flaring of HBV
infection [24].
We noted a higher mortality during the early phase of HAART in this study population. It is
possible that this effect is due to late presentation of patients with more advanced disease.
However, analysis restricted to only those who are taking Tenofovir suggests a beneficial
impact in those with HBV.
Tuberculosis is a common co-morbidity of HIV-infected patients and was an independent
predictor of mortality in the present study, in agreement with the results of other studies
across Africa [25–27]. It is known that the relative risk of anti-tuberculous therapy-induced
hepatotoxicity is higher in HBV/HIV co-infected patients than in HIV mono-infected
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individuals [28]. Symptomatic liver disease (particularly, jaundice) frequently prompts
patients to seek alternative drugs, a common feature in African HIV populations [29,30],
and/or which lead to treatment interruption and change to less potent regimens. If this had
contributed in deaths in the present study cohort, such patients might have died at home, or
away from the hospital affiliated to APIN and therefore may have be under represented in
our data set.
Male gender was a significant predictor of mortality in the study cohort. Men had lower
CD4 cell count at HAART commencement than women. Indeed, the CD4 cell count at
commencement of HAART has been found to correlate with response and ultimately,
survival [31]. Our data confirm this, as a significant trend of decreased death rate with
increasing CD4 cell count prior to commencing HAART was found. Additionally, studies
have reported that women generally do better than men to HIV treatment [32]. The
prevention of mother to child transmission of HIV (PMTCT) services, which predated the
onset of APIN, might have enabled more women to be used to HIV care and tolerating the
side effects of ARVs than men.
Limitations encountered in our study include the following: First, the causes of death were
not well ascertained as a result of suboptimal documentation. Precise dates of death of
several patients were not recorded and we depended on information from carers, Hope
Support and Tracking teams. We were thus limited in describing disease-specific deaths.
Whenever any of the patients had any serious illness, such as liver disease, they were
referred to specialist consultation in the affiliated hospital (JUTH). As no linkage of records
exists currently between JUTH and APIN, considerable amounts of information that would
have been relevant to our analyses may have been missed. Additionally, censoring subjects
who discontinued treatment, transferred to other centres of care and or lost to follow up may
have introduced bias to the obtained results.
Second, confirmation of HBV viraemic status by molecular methods was not carried out in
this population as this current study was designed to utilise already obtained data and
molecular diagnosis of hepatitis is not routine in the study population (we had shown, in an
unpublished data that HBV viraemia was positive in about 98% of HBsAg-positive
subpopulation of this study cohort). It would be of interest to appropriately categorise the
patients by their viraemic status, which would indeed enhance the power of this study.
In conclusion, HBV infection, tuberculosis and male gender were significantly associated
with mortality, following commencement of HAART therapy. Patients recruited during the
period, coinciding with increased access to Tenofovir-based treatment experienced less
deaths. Indeed, HBV was not a significant predictor of mortality in those patients that were
being administered Tenofovir-containing HAART. Long-term follow-up and enhanced
monitoring are needed to assess incidence of end-stage liver disease, hepatocellular
carcinoma and disease-specific deaths in this cohort. These data support an active approach
to identifying all HIV/HBV co-infected individuals in resource poor settings, if Tenofovir is
not routinely offered as first line treatment [33].
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Figure 1.
Profile of study cohort, AIDS Prevention Initiative in Nigeria, Jos University Teaching
Hospital, Nigeria, 2004–2010.
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Figure 2.
Kaplan-Meier survival curves according to hepatitis co-infection status for: both sexes; and
men; APIN 2004–2010; HBV: Hepatitis B virus; HCV: hepatitis C virus.
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